FindTrial
Sign In

A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequential regimen and low-dose multi-target regimen in the treatment of idiopathic membranous nephropathy

A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequential regimen and low-dose multi-target regimen in the treatment of idiopathic membranous nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048518
Enrollment
Unknown
Registered
2021-07-09
Start date
2021-10-31
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic membranous nephropathy

Interventions

low-dose multi-target group:No
tacrolimus combined with belimumab sequential group:No
intravenous cyclophosphamide pulse group:No

Sponsors

The Second Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years; 2. Diagnosed as idiopathic membranous nephropathy according to renal biopsy; 3. After two consecutive tests on different days, 24-hour urine protein>8g, and serum albumin4g; or after remission of previous immunosuppressive therapy, 24-hour urine protein>4g, serum albumin40 mL/min per 1.73m2; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.??????? 2.??????????????????????????????????; 3.???????????????????; 4.???????????,?????,?????????; 5.???????????????????; 6.?????(AST?ALT> 2.5??????????> 1.5?????); 7.???1?????????????????????; 8.?MMF?TAC?CYC??????????????; 9.?????????????????; 10.WBC??3*109/L?CD4+ ??????200 cells/ul?

Design outcomes

Primary

MeasureTime frame
remission rate;relapse rate;—

Secondary

MeasureTime frame
immunological response;—

Countries

China

Contacts

Public ContactFu Rongguo

The Second Affiliated Hospital of Xi'an Jiaotong University

pipifu@126.com+86 15291185506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026